Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 744

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 744
---
 | ​                 | ​ |  64,149 | ​ | ​ |
| Cash, cash equivalents and restricted cash at end of period                                                                | ​ | ​ | ​                  | $ |  38,561 | ​ | ​ | ​ | ​                 | $ |  64,783 | ​ | ​ |
| Noncash investing and financing activities                                                                                 | ​ | ​ | ​                  | ​ |       ​ | ​ | ​ | ​ | ​                 | ​ |       ​ | ​ | ​ |
| Incremental right-of-use asset in exchange for non-cash lease liability from modification of lease                         | ​ | ​ | ​                  | $ |   3,417 | ​ | ​ | ​ | ​                 | $ |       — | ​ | ​ |
| Initial direct costs included as right-of-use asset from modification of lease                                             | ​ | ​ | ​                  | $ |     577 | ​ | ​ | ​ | ​                 | $ |       — | ​ | ​ |
| Accrual for leasehold improvements                                                                                         | ​ | ​ | ​                  | $ |       — | ​ | ​ | ​ | ​                 | $ |     807 | ​ | ​ |

See Notes to Condensed Consolidated Financial Statements. F-6

TABLE OF CONTENTS

#### CARA THERAPEUTICS, INC.

### NOTES TO CONDENSED FINANCIAL STATEMENTS
<div align='center'>**(amounts in thousands, except share and per share data) 
 (unaudited)**</div>

### 1. Business
Cara Therapeutics, Inc., or the Company, is a biopharmaceutical corporation formed on July 2, 2004. The Company has been focused on leading a new treatment paradigm to improve the lives of patients suffering from chronic pruritus. The Company’s primary activities to date have been organizing and staffing the Company, developing its lead product and product candidates, including conducting preclinical studies and clinical trials of difelikefalin-based product candidates, and raising capital.

On June 14, 2024, the Board of Directors of the Company approved a streamlined operating plan exploring strategic alternatives focused on maximizing shareholder value after the Company announced its decision to discontinue the clinical program in notalgia paresthetica, or NP, on June 12, 2024. The Company’s decision to discontinue the clinical program in NP followed the outcome from the dose-finding Part A of the KOURAGE-1